🇺🇸 FDA
Pipeline program

TX200-TR101

TX200 KT02

Phase 2 mab active

Quick answer

TX200-TR101 for Kidney Transplant Rejection is a Phase 2 program (mab) at SANGAMO THERAPEUTICS, INC with 1 ClinicalTrials.gov record(s).

Program details

Company
SANGAMO THERAPEUTICS, INC
Indication
Kidney Transplant Rejection
Phase
Phase 2
Modality
mab
Status
active

Clinical trials